|
市場調査レポート
商品コード
1276313
腸疾患検査の世界市場規模、シェア、産業動向分析レポート:エンドユーザー別、疾患タイプ別、製品タイプ別(試薬・消耗品、機器)、検査手法別、地域別展望・予測、2023~2029年Global Enteric Disease Testing Market Size, Share & Industry Trends Analysis Report By End User, By Disease Type, By Product Type (Reagents & Consumables and Equipment), By Technique, By Regional Outlook and Forecast, 2023 - 2029 |
||||||
腸疾患検査の世界市場規模、シェア、産業動向分析レポート:エンドユーザー別、疾患タイプ別、製品タイプ別(試薬・消耗品、機器)、検査手法別、地域別展望・予測、2023~2029年 |
出版日: 2023年04月28日
発行: KBV Research
ページ情報: 英文 251 Pages
納期: 即納可能
|
腸疾患検査市場規模は、予測期間中にCAGR3.2%で成長し、2029年には46億米ドルに達すると予測されています。
腸疾患は、腸に影響を及ぼす細菌、ウイルス、寄生虫の微生物によって引き起こされます。これらの病気の多くは人から人へ感染する可能性があり、一般的には汚染された食べ物や飲み物を摂取することで発症します。腸内感染症の症状には、吐き気、腹痛、悪寒、発熱、下痢、食欲不振などがあります。
水や食品を媒介とする病気の多くは、腸内細菌が主な原因であることが分かっています。下痢や溶血性尿毒症症候群(HUS)は、世界的に一般的になってきています。腸内細菌感染症は最も頻度の高い原因です。腸内細菌性疾患検査市場は、下痢の発生率の上昇、新興国での発生率の上昇、政府の意識の高まり、政府や公的機関のさまざまな取り組みなどの要因により、予測期間を通じて拡大すると予想されます。
COVID-19の影響分析
COVID-19の検査と治療は、パンデミックがヘルスケアの優先順位に影響を与えた結果、腸疾患検査よりも優先されました。COVID-19のパンデミックは、COVID-19の検査、治療、ワクチン接種の取り組みに大規模な資源の再配分を必要としました。そのため、腸管疾患の検査など、ヘルスケアの他の領域から資源が流用されました。これは、ヘルスケア能力の低下や社会的距離の取り方など、さまざまな要因が重なったためです。COVID-19の流行により、腸疾患に関する多くの研究プロジェクトが中断され、資源や人材がCOVID-19の研究に流用されました。パンデミック時には腸管疾患検査キットの需要が減少し、市場成長にマイナスの影響を与えました。
市場成長要因
世界の腸疾患の有病率の増加
クロストリジウム・ディフィシル(C. difficile)、赤痢菌症、大腸菌、コレラ、サルモネラ症など、重度の下痢や死に至ることもある腸疾患の有病率が上昇していることも、これらの検査に対する需要の増加に寄与しています。世界中で毎年何百万人もの人々が腸管感染症に罹患していますが、特に衛生環境が整っていない低開発国で多く見られます。したがって、腸疾患の有病率の上昇は、予測期間を通じて市場の成長を促進すると考えられます。
研究開発の活発化に伴う技術的ブレークスルーの増加
腸疾患検査の需要は、腸疾患検査機器や検査方法の技術開発・改良が進むことで恩恵を受ける可能性があります。検査効率の向上、費用対効果の高い検査、迅速な検査結果は、製品開発に寄与する可能性があります。さらに、ヘルスケア事業では、より効率的で効果的、かつ手頃な価格のコンピューティングハードウェアが、ネットワーク接続の強化、ソフトウェアの改善、高度なセンサーに接続される傾向が強まっています。このことから、市場は今後数年間、これらの変数から財政的な利益を得る可能性があります。
市場抑制要因
検査とサンプリングにかかる高いコスト
自動化された腸疾患検査機器は、その高度な機能と特徴のため、手動式のものよりも高い価格設定となっています。メディア、機器、人件費を計算すると、特定のエンドユーザーには法外に高価と感じられるかもしれません。また、検査室に多数のシステムを導入することは、総資本コストの投資額を著しく増加させています。分子診断技術、特にマルチプレックスアッセイの活用は、シングルプレックスアッセイと比較して、ヘルスケア産業における最近の発展です。しかし、マルチプレックスアッセイ装置のコストは比較的高く、装置導入に必要な初期投資額も高くなります。この要因は、費用対効果の高い代替品が登場するまでは、市場の成長を阻害することになるでしょう。
製品タイプの展望
製品タイプ別に見ると、腸疾患検査市場は試薬・消耗品と機器に分類されます。2022年の腸疾患検査市場では、機器分野がかなりの成長率を確保しました。異なるタイプの腸疾患検査がプロセスで使用され、このセグメントの成長を推進しています。自動分析装置は、腸疾患の迅速な検査を実施するために使用されます。これらの検査は、サンプル中の病原体からの特定の抗原または遺伝物質の存在を検出することができます。
検査手法の展望
腸疾患検査市場は、検査手法別に分子診断と免疫診断に分類されます。免疫診断セグメントは、2022年に腸疾患検査市場で最大の収益シェアを獲得しました。免疫診断検査は、時には数時間という短時間で結果を出すことができるため、腸疾患の早期診断・治療が可能となります。免疫診断検査は、少量の病原体や抗体でも検出できるため、高感度で特異的な検査が可能です。つまり、特定の病原体の存在を正確に特定し、患者さんの症状の原因となる他の可能性を除外することができます。
疾患タイプ別の展望
腸疾患検査市場は、疾患タイプ別に細菌、ウイルス、寄生虫の3つに分類されます。サルモネラ症、コレラ、大腸菌、ヘリコバクター・ピロリなどの細菌性腸疾患の有病率の高さと、その診断のための腸疾患検査製品の普及が、この市場セグメントの成長を牽引しています。また、細菌腸疾患診断に関する知識の向上や、世界の細菌腸疾患の発生率の上昇により、このカテゴリーは急成長を遂げると予想されます。
エンドユーザーの展望
エンドユーザー別に見ると、腸疾患検査市場は、学術・研究機関、病院ラボ、製薬・バイオテクノロジー企業に分類されます。学術&研究機関セグメントは、2022年の腸疾患検査市場でかなりの収益シェアを獲得しました。学術・研究機関は、腸管疾患の公衆衛生監視において重要な役割を担っています。集団における腸管疾患の検査とモニタリングは、アウトブレイクの特定、対応計画の策定、予防・管理戦略の実施に役立ちます。研究機関は、腸疾患の原因となる新しい病原体の特定に重要な役割を果たします。
地域別の展望
地域別に見ると、腸疾患検査市場は、北米、欧州、アジア太平洋、LAMEAで分析されています。北米セグメントは、2022年の腸疾患検査市場において最大の収益シェアを記録しました。この地域における腸管疾患検査製品の製造技術の向上だけでなく、多くの重要なプレイヤーの存在が、市場の拡大を後押ししているのです。これは主に、腸疾患患者の増加、腸疾患の診断に関する研究に対する政府支援の増加、先進国における資本所得の大幅な増加によるものです。
市場参入企業がとる主な戦略は、買収です。カーディナルマトリックスで提示された分析に基づくと、Thermo Fisher Scientific, Inc.が腸疾患検査市場の先駆者です。Neogen Corporation、Bureau Veritas S.A.、Eurofins Scientific SEなどの企業は、腸管疾患検査市場における主要な革新的企業の1つです。
List of Figures
The Global Enteric Disease Testing Market size is expected to reach $4.6 billion by 2029, rising at a market growth of 3.2% CAGR during the forecast period.
Infections of the gastrointestinal tract, encompassing the small intestine, large intestine, and stomach, are known as enteric diseases. Bacteria, viruses, and parasites are just a few of the microorganisms that might cause these diseases. Salmonellosis, shigellosis, norovirus, rotavirus, amebiasis, cryptosporidiosis, and giardiasis are typical examples of enteric diseases. Others include cholera, Clostridium difficile (C. difficile), Escherichia coli (E. coli), shigellosis, and Helicobacter pylori (H. pylori).
To determine the exact pathogen triggering an enteric disease and to diagnose enteric diseases, numerous laboratory tests are employed. These tests often entail checking samples of blood, feces, or other fluids from the body for the presence of viruses, bacteria, and parasites known as enteric pathogens.
Enteric disorders are caused by bacterial, viral, and parasitic microorganisms that affect the intestines. Many of these illnesses can be spread from person to person and are typically brought on by consuming tainted food or drink. The symptoms of enteric infections include nausea, stomach pain, chills, fever, diarrhea, and loss of appetite.
One of the primary agents behind many water- and food-borne illnesses has been shown to be enteric bacteria. Diarrhea and hemolytic uremic syndrome (HUS) are becoming more common worldwide. Enteric bacterial infections are the most frequent cause. The enteric disease testing market is expected to expand throughout the forecast period due to factors such as rising rates of diarrhea, rising rates in emerging nations, higher government awareness, and various government and public sector initiatives.
COVID-19 Impact Analysis
COVID-19 testing and treatment took precedence over enteric illness testing as a result of the pandemic's impact on healthcare priorities. The COVID-19 pandemic required a massive redirection of resources towards COVID-19 testing, treatment, and vaccination efforts. This led to a diversion of resources away from other areas of healthcare, including enteric disease testing. This was due to a combination of factors, including reduced healthcare capacity, and social distancing measures. The COVID-19 pandemic disrupted many research projects related to enteric diseases, with resources and personnel being diverted towards COVID-19 research. The demand for enteric disease testing kits decreased during the pandemic, which negatively impacted market growth.
Market Growth Factors
Increasing prevalence of enteric disease worldwide
The rise in the prevalence of several other enteric diseases such as clostridium difficile (C. difficile), shigellosis, Escherichia coli (E. coli), cholera, and salmonellosis-all of which can result in severe diarrhea or even death-also contributes to the increasing demand for these tests. Rising Millions of people contract enteric infections every year worldwide, but they are particularly prevalent in underdeveloped nations with subpar sanitation. Hence, the rising prevalence of enteric disease will propel the growth of the market throughout the forecast period.
Rising number of technological breakthroughs owing to increased R&D
The demand for enteric disease testing may benefit from the growing technological developments and improvements in enteric disease testing equipment and methods. Testing efficiency gains, cost-effective testing, and quick test results may contribute to product development. Additionally, the healthcare business is embracing the growing trend of more efficient, effective, and affordable computing hardware connected to greater network connectivity, improved software, and advanced sensors. In light of this, the market may benefit financially from these variables in the years to come.
Market Restraining Factors
High cost of testing and sampling
Automated enteric disease testing instruments are priced higher than their manual counterparts due to their advanced features and functions. The calculated cost of the media, instrument, and labor may be perceived as prohibitively expensive by certain end users. In addition, implementing numerous systems in testing laboratories has significantly increased the total capital cost investment. Utilizing molecular diagnostic techniques, particularly multiplexed assays, is a recent development in the healthcare industry compared to singleplex assays. However, the cost of multiplexed assay equipment is comparatively high, and the initial investment required for instrument installation is higher. This factor will impede the market's growth until cost-effective alternatives become available.
Product Type Outlook
Based on product type, the enteric disease testing market is characterized into reagents & consumables and equipment. The equipment segment procured a considerable growth rate in the enteric disease testing market in 2022. Different types of enteric disease testing are used in the process, which is propelling the growth of the segment. Automated analyzers are used to perform rapid tests for enteric diseases. These tests can detect the presence of specific antigens or genetic material from the pathogen in a sample.
Technique Outlook
On the basis of technique, the enteric disease testing market is classified into molecular diagnostics and immunodiagnostics. The immunodiagnostics segment acquired the largest revenue share in the enteric disease testing market in 2022. Immunodiagnostic tests can provide results quickly, sometimes in as little as a few hours, which allows for earlier diagnosis and treatment of enteric diseases. Immunodiagnostic tests can detect even small amounts of pathogens or antibodies, making them highly sensitive and specific. This means they can accurately identify the presence of a specific pathogen and rule out other potential causes of the patient's symptoms.
Disease Type Outlook
By disease type, the enteric disease testing market is divided into bacterial, viral, and parasitic. The high prevalence of bacterial enteric diseases such as salmonellosis, cholera, E. coli, and Helicobacter pylori, as well as the widespread utilization of enteric disease testing products for the diagnosis, are driving the growth of this market segment. In addition, due to increased knowledge of bacterial enteric disease diagnosis and a rising incidence of bacterial enteric diseases globally, the category is anticipated to experience rapid growth.
End User Outlook
Based on end user, the enteric disease testing market is segmented into academic & research institutes, hospital laboratories, and pharmaceutical & biotechnology companies. The academic & research institutes segment acquired a substantial revenue share in the enteric disease testing market in 2022. Academic and research institutes play a vital role in public health surveillance for enteric diseases. Testing and monitoring of enteric diseases in populations can help in identifying outbreaks, developing response plans, and implementing prevention and control strategies. Research institutes play a crucial role in identifying new pathogens responsible for enteric diseases.
Regional Outlook
Region wise, the enteric disease testing market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment recorded the largest revenue share in the enteric disease testing market in 2022. The presence of a number of significant players as well as improvements in the manufacturing technology of enteric disease testing products in the region is what is driving the market's expansion. This is mostly due to an increase in the number of patients with enteric diseases, increased government support for research into the diagnosis of enteric diseases, and a sizable increase in capital income in industrialized nations.
The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Thermo Fisher Scientific, Inc. is the forerunner in the Enteric Disease Testing Market. Companies such as Neogen Corporation, Bureau Veritas S.A., and Eurofins Scientific SE are some of the key innovators in Enteric Disease Testing Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Thermo Fisher Scientific, Inc., SGS S.A., Eurofins Scientific SE, Bureau Veritas S.A., Intertek Group PLC, TUV Nord Group, PerkinElmer, Inc., Becton, Dickinson and Company and Neogen Corporation.
Recent Strategies Deployed in Enteric Disease Testing Market
Mergers and Acquisitions:
Jan-2023: Thermo Fisher Scientific Inc. took over The Binding Site Group, a global leader in specialty diagnostics. Through this acquisition, Thermo Fisher Scientific Inc. would be able to extend its current specialty diagnostics portfolio along with pioneering innovation in monitoring and diagnostics for numerous myelomas.
Sep-2022: Bureau Veritas took over Galbraith Laboratories, a US-based operator of contract analytical testing. The addition of Galbraith expands the acquiring company's market presence in the personal care, industrial, and consumer healthcare markets, and further expands Bureau Veritas' market position in the North American region.
Sep-2022: Neogen announced the completion of a merger with 3M's Food Safety business. 3M's food safety business is merged with Neogen. The combination expands the merged company's geographical footprint, digitization capabilities, etc.
Jul-2022: Neogen completed the acquisition of Thai-Neo Biotech, a Thailand-based distributor of food safety products. The acquisition enables the acquiring company to establish a direct presence in Thailand and the Southeast Asian region. Further, the addition of Thai-Neo Biotech perfectly complements Neogen's operations in China, Australia, and India.
Jun-2022: Eurofins acquired a majority stake in Ajal for Laboratories, a Saudi Arabia-based provider of laboratory services. This acquisition broadens the acquiring company's food and pharmaceutical product test offerings in Saudi Arabia. Further, the acquisition reflects Eurofins' commitment to developing a local and regional laboratory network across the whole Middle East.
Sep-2021: Neogen acquired CAPInnoVet, a US-based provider of animal health medicines and products. This acquisition provides Neogen entry to the retail parasiticide market. The acquired company will be a part of Neogen's Animal Safety business segment.
Apr-2021: Thermo Fisher Scientific Inc. took over PPD, Inc., a pharmaceutical company engaged in clinical research. Through this acquisition, the company would provide a vast range of services in the clinical development spectrum. This includes the development and manufacturing of the drug product, healthcare outcomes, trial logistics., scientific discovery, etc.
Partnerships, Collaborations and Agreements:
Oct-2022: Thermo Fisher Scientific came into partnership with Genoox, a provider of fast and accurate tools to solve complex, genomic data challenges, delivering advanced, and end-to-end genomic analysis tools. The partnership aims to automate the interpretation and reporting of cytogenetic research data with AI. ChAS users can access Franklin, Genoox's cloud-based AI platform with the launch of CytoScan Automated Interpretation and Reporting (AIR) solution for making cytogenetic research data analysis easy.
Apr-2022: SGS came into partnership with Liveome, a South Korea-based operator of microbiome research-based firm. The partnership focuses on the development and commercialization of LIV001, an inflammatory bowel disease (IBD) candidate. The partnership demonstrates SGS' ability to provide its services globally.
Product Launches and Expansions:
Dec-2022: Thermo Fisher introduced TrueMark Infectious Disease Research Panels, developed to enable quick and precise detection and categorization for investigating microorganisms. The new panel are real-time polymerase chain reaction (PCR) syndromic panels and gives an option to the user to choose between standard or custom panels.
Oct-2022: Thermo Fisher launched TaqPath Enteric Bacterial Select Panel, a CE-IVD marked test intended for common Gastrointestinal bacteria. The new test detects gastrointestinal (GI) bacteria and speeds up the root cause identification process. The GI bacteria detecting test is based on polymerase chain reaction (PCR) technology to examine the stool samples. The test can deliver results with 98% specificity, and sensitivity within two hours.
Market Segments covered in the Report:
By End User
By Disease Type
By Product Type
By Technique
By Geography
Companies Profiled
Unique Offerings from KBV Research